THE UNIVERSITY OF TEXAS MEDICAL BR.
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $47.3M
- Transactions
- 3,187
- Companies
- 40
- Average per transaction
- $14,830
Who reported the payments
| Pfizer | $21,280,098 |
| Gilead | $3,467,275 |
| Merck | $3,445,788 |
| Emergent Biosolutions Inc. | $2,200,210 |
| Getinge USA Sales, LLC | $1,617,671 |
| Eli Lilly | $1,502,151 |
| Modernatx, Inc. | $1,342,137 |
| Mitsubishi Tanabe Pharma Development America, Inc. | $965,921 |
| AstraZeneca | $802,631 |
| Apollo Endosurgery US Inc | $770,824 |
| Siemens Medical Solutions USA, Inc. | $706,113 |
| Abbott | $666,298 |
| Agilent Technologies, Inc. | $637,701 |
| Luminex Corporation | $595,812 |
| Intuitive Surgical | $486,766 |
| Tanabe Pharma America, Inc. | $485,012 |
| Cepheid | $473,353 |
| Maquet Cardiopulmonary GmbH | $379,799 |
| Medicem Inc. | $302,798 |
| Medtronic | $252,415 |
| Boston Scientific | $223,817 |
| Sanofi Pasteur Inc. | $219,847 |
| Novartis | $218,841 |
| Invivyd Inc | $202,397 |
| Takeda Pharmaceuticals U.S.A., Inc. | $201,009 |
| Biotronik Inc. | $193,065 |
| Sysmex America, Inc. | $176,907 |
| Alnylam Pharmaceuticals Inc. | $173,522 |
| Janssen Research & Development, LLC | $161,515 |
| Epizyme, Inc. | $154,919 |
| Bayer | $138,670 |
| Roche Diagnostics Operations, Inc. | $137,874 |
| Stryker | $137,372 |
| Astrazeneca AB | $137,022 |
| Amgen | $129,672 |
| Endologix LLC | $118,814 |
| PTC Therapeutics, Inc. | $108,614 |
| Masimo Corporation | $93,226 |
| E.r. Squibb & Sons, L.L.C. | $90,302 |
| Microvention, Inc. | $82,442 |